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Abbreviations 
AFP, α-fetoprotein; AFP-L3, core-fucosylated AFP; ALB, albumin; ALT, alanine aminotransferase; 
APTS, 8-aminonaphtalene-1, 3, 6-trisulphonic acid; AUC, area under the curve; BBD, benign biliary 
disease; CA125, carbohydrate antigen 125; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate 
antigen 72-4; CCA, cholangiocarcinoma; CE, capillary electrophoresis; CEA, carcinoembryonic 
antigen; DMSO, dimethyl sulfoxide; DSA-FACE, DNA sequencer-assisted fluorophore-assisted 
capillary electrophoresis; ECCA, extrahepatic cholangiocarcinoma; GLU, glucose; HC, healthy 
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control; HCC, hepatocellular carcinoma; MS, mass spectrometry; NaBH3CN, sodium 
cyanoborohydride; NPV, negative predictive value; PLT, platelet; PNGaseF, peptide N-glycosidase-F; 
PPV, positive predictive value; PSA, prostate-specific antigen; ROC, receiver operating characteristic; 
TBIL, total bilirubin; TP, total protein. 
Abstract 
Extensive efforts have been devoted to improve the diagnosis of extrahepatic cholangiocarcinoma 
(ECCA) due to its silent clinical character and lack of effective diagnostic biomarkers. Specific 
alterations in N-glycosylation of glycoproteins are considered a key component in cancer progression, 
which can serve as a distinct molecular signature for cancer detection. This study aims to find potential 
serum N-glycan markers for ECCA. In total, 255 serum samples from patients with ECCA (n=106), 
benign bile tract disease (BBD, n=60) and healthy control (HC, n=89) were recruited. Only 2μl of 
serum from individual patients was used in this assay where the N-glycome of serum glycoproteins was 
profiled by DNA sequencer-assisted fluorophore-assisted capillary electrophoresis (DSA-FACE) 
technology. Multi-parameter models were constructed by combining the N-glycans and carbohydrate 
antigen 19-9 (CA19-9) which is currently used clinically. Quantitative analyses showed that among 13 
N-glycan structures, the bifucosylated triantennary N-glycan (peak10, NA3F2) presented the best 
diagnostic performance for distinguishing ECCA from BBD and HC. Two diagnostic models 
(Glycotest1 and Glycotest2) performed better than single N-glycan or CA19-9. Additionally, two 
N-glycan structures (peak9, NA3Fb; peak12, NA4Fb) were tightly related to lymph node metastasis in 
ECCA patients. In conclusion, sera of ECCA showed relatively specific N-glycome profiling patterns. 
Serum N-glycan markers and models are novel, valuable and noninvasive alternatives in ECCA 
diagnosis and progression monitoring. 
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1. Introduction 
Cholangiocarcinoma (CCA) accounts for about 3% gastrointestinal malignancies. It arises from the 
epithelium of either intrahepatic or extrahepatic bile ducts and can be divided into intra- (ICCA) or 
extra-hepatic CCA (ECCA) anatomically [1]. Approximate 80-90% of CCA were ECCA and could be 
further subdivided into perihilar CCA or distal CCA, separated by the insertion of the cystic duct [2]. A 
lot of risk factors including primary sclerosing cholangitis, bile duct abnormalities, infection, metabolic 
disorders and genetic susceptibility have been reported to be associated with ECCA, but no specific 
predisposing factors have been identified up to now [3, 4]. ECCA is a relatively uncommon but highly 
malignant cancer with the incidence of 0.82/100,000 in the United States [5]. At present, complete 
resection remains the most effective and only potentially curative treatment for ECCA, but most 
patients present with advanced unresectable disease mainly due to the lack of reliable serum biomarkers 
[6]. In spite of multiple studies on novel molecules for diagnosis in ECCA, the progress in clinical 
translation has so far been limited. The overall prognosis of ECCA patients is reportedly dismal with the 
median survival less than 24 months and once diagnosed, few cases could survive for more than 5 years 
[5, 7]. Thus, more precise markers with high sensitivity and specificity for ECCA are in urgent need 
which will benefit the patients and expedite the discovery of novel therapeutic strategies. 
Glycosylation, one of the most common co- and post-translational modifications, has been 
reported to play vital roles in a variety of physiopathological conditions, including intercellular 
adhesion, cell migration, cell-cell signaling, host-microbial interaction and inflammation [8-10]. 
Accumulated evidences reveal that aberrant glycosylation is associated with the oncogenesis and 
progression of various cancers and this modification is the characteristic of serum glycoproteins in 
cancer patients [11-13]. As a result, altered glycans related to a specific cancer would make these 
glycans or their carriers potential tumor biomarkers [14-18]. In fact, most cancer biomarkers applied to 
clinical care are glycoproteins bearing N-glycosylation modifications such as prostate-specific antigen 
(PSA) and alpha-fetoprotein (AFP) [19, 20]. AFP is a commonly used tumor biomarker for 
hepatocellular carcinoma (HCC), and the result of aberrant N-glycosylation of AFP, core-fucosylated 
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AFP (AFP-L3) is more specific than AFP and is negative for most benign liver diseases [20, 21]. 
Approved by the FDA as a clinical biomarker for HCC in 2005, AFP-L3 might trigger a new era of 
glycan or glycoprotein biomarker discovery [22, 23].  
Numerous techniques and methods have been established to identify and quantify variation of 
N-glycans in glycoproteins [24, 25]. However, most of these approaches involve chromatographic 
separation, mass spectrometry analysis or various microarrays, along with high complexity and low 
cost-efficiency [26-28]. Herein, we employ a modified DNA sequencer-assisted fluorophore-assisted 
capillary electrophoresis (DSA-FACE) technology, which is originally established by Callewaert and 
coworkers to decipher the global N-glycome of serum [29-31]. Discovery of differentially expressed 
glycans from whole serum may serve to present candidate biomarkers for the discrimination of ECCA. 
2. Materials and methods 
2.1 Case selection and blood samples 
A total of 166 patients with ECCA (n=106) and benign bile tract disease (BBD, n=60) who underwent 
surgical resection at Eastern Hepatobiliary Hospital (EHBH), Shanghai from 2010 to 2012 were 
enrolled in our study. The histologic slides were retrieved and the diagnosis for each case was 
confirmed by two independent pathologists. Clinical staging is based on the TNM 
(tumor-node-metastasis) staging systems of the American Joint Committee on Cancer (AJCC, 7th 
edition) [32]. Demographic, clinical information and histologic characteristics for each patient were 
obtained from electronic medical record. For a healthy control (HC) group, 89 healthy volunteers who 
visited the same hospital for a regular physical examination were enrolled. We defined a healthy 
individual as someone who was deemed free of disease (including no history of cancer) at health 
check-up. Blood was collected using a standard protocol and serum samples were separated by 
centrifuging at 3000 rpm for 10 min, and then stored at −80°C. The study protocol was approved by the 
Chinese Ethics Committee of Human Resources, EHBH. Informed consents were obtained from the 
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patients and the healthy donors in advance. The main clinical and biochemical data of the study 
population were summarized in Table 1. 
2.2 Laboratory tests and clinical information 
Routine biochemical tests including total bilirubin (TBIL), total protein (TP), albumin (ALB), alanine 
aminotransferase (ALT) and glucose (GLU) were measured using standard methods and respective 
reagents recommended by the manufacturer (Hitachi 7600 Analyzer, Hitachi, Japan; Wako Diagnostics 
reagents, Wako Pure Chemical Industries Ltd., Japan). Tumor markers such as CA19-9, 
carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 72-4 (CA72-4) and 
carbohydrate antigen 125 (CA125) were determined on Roche E170 modular with matched reagents 
(Roche E170, Germany).  
2.3 Serum protein N-glyome profiling 
Serum protein N-glycan analysis was performed using DSA-FACE technology as described previously 
[33, 34]. Briefly, the N-glycans present on glycoproteins in 2μl of serum were released with peptide 
N-glycosidase-F (PNGaseF) (New England Biolabs, Boston, MA). Afterwards, the dried N-glycans 
were labeled with 8-aminonaphtalene-1, 3, 6-trisulphonic acid (APTS) (Invitrogen, Carlsbad, CA) 
using 2μl labeling solution (equal mixture of 20mM APTS in 1.2M of citric acid and 1M of NaBH3CN 
in DMSO) and incubated for 16 hours at 37°C. Sialic acid was then removed with 3μl 
neuraminidase/sialidase (Roche Bioscience, Palo Alto, CA) at a final concentration of 0.2mU in 5mM 
ammonium acetate and incubated at 37°C overnight. Finally, the processed N-glycans were separated 
using 3500 Series Genetic Analyzer (Applied Biosystems, Foster city, CA) and the peaks were 
analyzed via the GeneMapper v4.1 software (Applied Biosystems, Foster city, CA). The abundance of 
each N-glycan peak was quantified by normalizing its height to the sum of the heights of all 13 peaks 
based on a previous method which has been approved to relatively quantitate abundance [31, 35]. 
2.4 Statistical Analysis 
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All quantitative variables were expressed as median, (centile 25, centile 75) unless otherwise stated, 
categorical variables were expressed as number (percentage). Quantitative variables were compared 
with Student t test, ANOVA or nonparametric test. Pearson coefficients of correlation (spearman 
coefficients of correlation were calculated for ordinal categorical variables) and their associated 
probabilities (p) were used to evaluate the relationship between parameters. Forward stepwise logistic 
regression analysis was performed to construct the diagnostic multi-parameter models. The receiver 
operating characteristic (ROC) curve analysis was carried out and the area under curve (AUC) was 
presented to evaluate the diagnostic efficacy of each single marker or multi-parameter model. 
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy 
were calculated using cut-off values optimally determined upon the ROC curves. All reported p values 
were 2-tailed, and a p value less than 0.05 was considered statistically significant. Statistical analysis 
was performed with SPSS 21.0 for Windows software (IBM Corporation, Armonk, NY). 
3. Results 
3.1 Different profiling patterns and diagnostic powers of N-glycome in ECCA, BBD and HC 
group 
By DSA-FACE, the N-glycan profiling of desialylated sera from subjects in the ECCA (n=106), BBD 
(n=60), and HC (n=89) groups were quantitatively examined and statistically compared. Thirteen 
N-glycan structures (peaks) were identified in the samples of each group (Figure 1). Structural analysis 
of these peaks was performed by correlating the migration time of N-glycans to those of dextran ladders 
as previously reported [31, 35]. The average relative abundance of these N-glycans is summarized in 
Table 2. Different N-glycan structures of serum total glycoprotein in three groups suggested that 
different N-glycan patterns appeared in specific pathophysiologic conditions and indicated the 
possibility of N-glycans as diagnostic markers. Compared to the HC group, peak1 (NGA2F), peak2 
(NGA2FB), peak4 (NG1A2F), peak9 (NA3Fb), peak9’ (NA3F), peak10 and peak12 (NA4Fb) were 
elevated (p<0.05), whereas the other peaks (except peak7, NA2FB) were decreased in the ECCA group 
(p<0.05). When comparing the N-glycome of the ECCA and BBD group, the abundance of peak3 
  
 
This article is protected by copyright. All rights reserved. 
 
(NG1A2F), peak7 and peak11 (NA4) were decreased in the ECCA group while the abundance of 
peak9, peak9’, peak10, peak11 and peak12 were increased in ECCA patients.  
Diagnostic powers of N-glycans for differentiating ECCA from HC and BBD were calculated by 
ROC curves and AUC analysis. In ROC analysis, peak9, peak9’, peak10 and peak12 performed 
effectively in both diagnosis and differential diagnosis for ECCA (Supplementary Figure 1; AUC>0.7 
was recognized as the threshold value). Peak10, a bifucosylated triantennary structure, showed the best 
diagnostic power among all 13 N-glycan peaks to distinguish ECCA from HC with the AUC of 0.948 
(95% Confidence interval (95% CI): 0.918-0.978; Figure 2A). In addition, peak10 also revealed the 
best power to distinguish ECCA from BBD patients and the AUC was 0.909 (95% CI: 0.864-0.955; 
Figure 2B)  
3.2 Serum N-glycans were correlated with clinical and pathological characteristics. 
Apart from the diagnostic value of N-glycan based markers, the correlation between N-glycans and 
clinical laboratory testing data or pathological characteristics was also explored. The coefficients of 
correlation and corresponding p value were listed in Supplementary Table 1. Lymph nodes status is a 
strong determinant of clinical outcomes for patients with various gastrointestinal cancers [36, 37]. 
Intriguingly, we noticed that a branching fucosylated triantennary N-glycan (peak9, AUC=0.845) and a 
branching fucosylated tetra-antennary N-glycan (peak12, AUC=0.761) were positively correlated with 
lymph node involvement (p<0.05), whereas CA19-9, the commonly used marker, was not related to this 
pathological feature. Although both peak9 and peak12 were less helpful than CA19-9 in diagnosis 
(Supplementary Figure 1), they were more efficient than CA19-9 (AUC=0.660) in predicting lymph 
node involvement (Figure 3), indicating that N-glycans might play a critical role in progression of 
ECCA and can be used for prognosis assessment. 
 
3.3 Construction and assessment of diagnostic models based on N-glycan markers for ECCA 
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To date, CA19-9 was the most frequent and effective tumor marker for identifying ECCA in routine 
clinical screening and tests, so we compared N-glycan markers with CA19-9. Based on ROC curves in 
Figure 2, the optimum cut-off value of peak10 was 0.38 (accuracy 88.2%) and 0.49 (accuracy 79.5%) 
when used to identify ECCA from HC and BBD, respectively. As shown in Table 3 and Table 4, peak10 
performed better than CA19-9 in sensitivity (86.8% vs 83.0%) but not in specificity (90.0% vs 100.0%) 
to distinguish ECCA patients from normal controls. However, when used to separate ECCA from BBD 
patients, peak10 showed higher specificity (90.0% vs 83.3%) but lower sensitivity (73.6% vs 83.0%) 
than CA19-9.  
To discover ideal diagnostic efficiencies, mathematical diagnostic models were constructed by 
combining N-glycan markers and CA19-9. Logistic regression coefficients were used to estimate odds 
ratios (OR) for each of the independent variables. Eventually, a mathematic formula named Glycotest1 
was constructed to separate ECCA patients from normal controls 
(Glycotest1=0.089*CA19-9+11.444*peak10-0.331*peak5-0.540*peak6+17.058). To assess the 
contribution of Glycotest1 in differentiating ECCA, we determined the areas under the ROC curves. 
Compared with CA19-9 (AUC=0.918), Glycotest1 was more effective in identifying ECCA from 
normal controls at the cut-off value of 1.83 (AUC=0.992, Figure 2A). Table 3 listed the sensitivity, 
specificity, PPV, NPV, and accuracy of Glycotest1 for predicting ECCA. The diagnostic accuracy of 
Glycotest1 was 94.4%, whereas 90.8% of single CA19-9. Similarly, another mathematical formula 
named Glycotest2 was established to differentiate ECCA from BBD (Glycotest2 
=0.009*CA19-9+9.112*peak10-4.370), and the diagnostic parameters of Glycotest2 were given in 
Table 4. When using the optimum diagnostic cut-off value of 0.56 based on ROC analysis (Figure 2B), 
Glycotest2 improved the diagnostic accuracy of CA19-9 (83.1%) and peak10 (79.5%) to 88.0%. 
 
Follow-up of changes of N-glycan markers and CA19-9 of ECCA patients before and after 
surgery 
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After surgery, ECCA patients were followed up and a blood sample was obtained 7-14 days after 
treatment. The abundance of structures in peak1, 3, 4, 11 and 12 increased significantly after surgery 
versus before surgery by the DSA-FACE analysis (Supplementary Figure 2). Conversely, the 
postoperative abundance of peak2, 7 and 8 (NA3) was lower than those of preoperative samples. There 
was no significant difference in serum CA19-9 levels before and after surgery. These results presented 
the clues again that N-glycan markers might be used to monitor the progression and predict the 
prognosis of ECCA. 
 
Discussion 
ECCA is a rare but challenging cancer with poor prognosis. Early diagnosis plays a pivotal role in 
treating and managing ECCA cases [38, 39]. CA 19-9 is the most commonly used ECCA marker, but it 
does not provide sufficient sensitivity and reliability for early detection [1, 2]. As most other cancer 
biomarkers in use today, CA19-9 is a glycoprotein and measured immunochemically using monoclonal 
antibodies. However, the epitope for these antibodies were mostly designed against the protein moiety 
and not towards the N-glycan structures [17]. To date, N-glycan based biomarkers or models have been 
developed to help validate diagnosis and evaluate outcome for various cancers or other illnesses 
including liver cancer [33], rectal carcinoma [34, 40], ovarian cancer [41] and lung cancer [42]. Some 
reviews have highlighted the promising prospect of N-glycans as cancer biomarkers and the progress in 
glycomic research strategies recently [14, 18, 19]. Therefore, we believe that N-glycans could be more 
effective than individual glycosylated molecules for detecting ECCA occurrence and development.  
In current research, a simple and practical N-glycan analysis technology, DSA-FACE, was 
adopted for measuring N-glycosylation changes in serum from ECCA patients, BBD patients, and 
healthy volunteers. We tried to identify the specific N-glycan profiling patterns occurring in the process 
of carcinogenesis and progression of ECCA. As shown in the results, differentially-expressed N-glycan 
structures of serum glycoprotein in three groups were found (Figure 1, Table 2). In order to determine 
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diagnostic value, we compared the N-glycosylation characteristics of ECCA with HC and BBD 
separately. A bifucosylated triantennary N-glycan (peak10) performed best among all 13 peaks in 
diagnosis and differential diagnosis for ECCA and acted better in some aspects than CA19-9 (Figure 2, 
Table 3&4). Previously, this N-glycan structure has also been reported to be a potential biomarker for 
liver cancer [23] and pancreatic cancer [43, 44]. To enhance diagnostic accuracy, N-glycans were 
combined with CA19-9 using mathematical models to identify ECCA from BBD patients and the 
healthy controls. Eventually, the models Glycotest1 and Glycotest2 were screened out and remarkably 
improved the accuracy of the single-marker index (CA19-9 or peak10) with AUC of 0.992 and 0.938, 
respectively (Figure 2, Table 3&4). Thus, both combined-marker methods demonstrated higher 
accuracy in discriminating ECCA from BBD than any individual marker alone.  
As is well-known, assessment of nodal status might harbor important prognostic information and 
guided adjuvant treatment [36, 37]. Correlation analyses and ROC curves indicated that a branching 
fucosylated triantennary N-glycan (peak9) and branching fucosylated tetra-antennary N-glycan 
(peak12) were closely related with lymph metastasis. Conversely, CA19-9 could not reflect the status of 
regional lymph nodes (Figure 3). These branching/outer-arm fucosylation structures have been reported 
to be associated with ovarian cancer [41] and liver cancer [45, 46]. The findings implied the 
participation of N-glycans in oncogenesis and progression of ECCA. 
In exploring the dynamic monitoring value of N-glycan markers, peaks of N-glycans and levels of 
CA19-9 in ECCA were compared before and after surgical treatment (Supplementary Figure 2). 
Changes of the abundance of some N-glycans pre- and post-operation proved the tumor specificity of 
certain structures and could be used in therapeutic observation, recurrence monitoring, and prognosis 
evaluation.  
In this research, relatively specific N-glycan patterns of ECCA referring to BBD and normal 
individuals were identified by an efficient approach. This global N-glycomic strategy aimed to release 
and analyze the whole N-glycome from serum glycoproteins using enzymatic means without a 
pre-processing step for depletion of high-abundance proteins in serum, which avoids sample loss. We 
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observed the diagnostic value of N-glycans for ECCA and constructed two formulas to enhance the 
accuracy. The relationships between N-glycan markers and clinicopathological parameters, especially 
lymph node involvement suggested the potential of N-glycans as the monitoring indicators and 
underlying therapeutic targets. However, it should be noted that some limitations still existed in our 
study. Limited to the strategy and instrument, a relatively low number of N-glycans were determined 
and further differentiation of the specific isomers could not be achieved without combining capillary 
electrophoresis (CE) with mass spectrometry (MS) or MS/MS. However, the DSA-FACE method 
remains an effective glycomic approach for the discovery of cancer biomarkers. Differential 
biomarkers of clinical application potential can be identified with simple structural information using 
this method with higher repeatability and better quality control than the original method, as previously 
reported [30, 33]. Aberrant sialylation has been implicated in several cancers [47, 48]. However, 
desialylation reaction is adopted prior to the analysis, because sialic acids add negative charge on the 
N-glycans, which is a limitation in many CE-based methods. On the other hand, sialic acids add to the 
enormous heterogeneity of the N-glycans, and removal of sialic acids may thus add to the readability in 
complex mixtures, especially for N-glycans cleavaged from serum glycoproteins. Some groups have 
reported their strategies and methods for analyzing sialylated N-glycan linkage isomers, and these 
methods could be applied to discover the potential biomarkers with sialic linkage specific manner 
[49-51]. Further research for protein-specific or site-specific glycan markers, including sialic acid 
information may be carried out in the future. 
 
 
 
Conclusion 
N-glycan profiles of ECCA differ from the profiles of benign diseases and healthy controls. N-glycan 
based biomarkers and models are promising, noninvasive serum diagnostic tools and valuable 
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supplements to the serologic biomarkers already in use. Future in-depth study may investigate the 
prognostic and therapeutic value of N-glycans for ECCA and the mechanisms involved in pathogenesis.  
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Figure Captions 
Figure 1. A representative N-glycome profiling for total serum glycoproteins. Thirteen peaks were 
identified. The structure of each peak were shown below the panel. 
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Figure 2. ROC curves for the detection of ECCA. Figure 2A shows the ROCs of single parameter 
including CA19-9 (AUC=0.918), peak10 (AUC=0.948) and the diagnostic model Glycotest1 
(AUC=0.992) for identifying ECCA from HC. Figure 2B shows the ROCs of CA19-9 (AUC=0.851), 
peak10 (AUC=0.909) and the model Glycotest2 (AUC=0.938) for distinguishing ECCA from BBD. 
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Glycotest1=0.089*CA19-9+11.444*peak10-0.331*peak5-0.540*peak6+17.058; 
Glycotest2=0.009*CA19-9+9.112*peak10-4.370. 
A B
 
 
 
 
 
 
 
Figure 3. ROC curves of peak 9, peak 12 and CA19-9 for the detection of ECCA with lymph nodes 
involvement (AUCpeak9=0.845, AUCpeak12=0.761, AUCCA19-9=0.660). 
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Tables 
Table 1. Demographic and clinical characteristics of study population 
Variables 
ECCA
 
(n=106) 
BBD
 
(n=60) 
HC
 
(n=89) 
P 
ECCA vs BBD ECCA vs HC 
Age (years) 58.50, (51.00, 64.00) 53.00, (35.25, 58.00) 42.00, (31.50, 49.00) <0.05 <0.05 
TBIL (μmol/L) 129.90, (38.55, 244.65) 11.70, (9.30, 16.95) 12.30, (10.00, 15.25) <0.001 <0.001 
TP (g/L) 67.50, (62.35, 72.80) 71.40, (67.85, 75.05) 77.00, (74.00, 79.65) 0.002 <0.001 
ALB (g/L) 39.40, (36.40, 42.15) 41.60, (39.40, 45.05) 47.00, (45.90, 48.65) <0.001 <0.001 
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ALT (IU/L) 109.60, (64.40, 205.45) 20.00, (14.55, 32.90) 16.00, (11.15, 26.50) <0.001 <0.001 
GLU (mmol/L) 5.45, (4.97, 6.28) 4.93, (4.64, 5.29) 4.94, (4.58, 5.20) <0.001 <0.001 
PLT(10^9/L) 250.00, (239.78, 272.51) 213.00, (195.01, 235.23) 216.50, (205.44, 226.70) 0.004 0.001 
CA19-9 (U/ml) 166.10, (50.30, 470.10) 10.70, (4.53, 26.53) 7.20, (4.15, 15.43) <0.001 <0.001 
CEA (μg/L) 2.70, (1.80, 5.30) 1.50, (0.88, 2.13) 1.65, (0.88, 1.88) <0.001 <0.001 
AFP (μg/L) 2.90, (2.10, 4.10) 2.25, (1.63, 3.00) 2.20, (1.58, 3.55) 0.370 0.290 
CA72-4 (U/ml) 1.80, (1.20, 5.60) 1.30, (0.90, 2.50) 1.85, (0.90, 2.73) 0.007 0.004 
CA125 (U/ml) 14.30, (10.90, 21.9) 13.75, (8.30, 18.35) 12.50, (10.05, 19.03) 0.113 0.038 
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Table 2. General N-glycome profiling results in 3 different groups 
Variables 
ECCA  BBD  HC  P 
(n=106) (n=60) (n=89) ECCA vs BBD ECCA vs HC 
Peak1 (NGA2F) 7.44, (5.98, 9.91) 8.01, (5.74, 10.07) 6.40, (5.09, 7.83) 0.775 <0.001 
Peak2 (NGA2FB) 1.165, (0.96, 1.48) 1.20, (0.87, 1.55) 0.97, (0.74, 1.21) 0.814 <0.001 
Peak3 (NG1A2F) 5.76 (4.81, 6.64) 6.65, (5.44, 7.32) 6.29, (5.58, 7.01) 0.001 0.001 
Peak4 (NG1A2F) 5.44, (4.92, 6.33) 5.41, (4.97, 6.10) 5.08, (4.53, 5.81) 0.961 0.002 
Peak5 (NA2) 38.22, (35.39, 41.56) 37.28, (35.12, 40.04) 39.35, (37.44, 41.635) 0.35 0.038 
Peak6 (NA2F) 19.22, (17.18, 21.28) 20.24, (17.78, 22.56) 21.80, (19.78, 24.23) 0.052 <0.001 
Peak7 (NA2FB) 5.23, (4.62, 6.31) 6.16, (5.03, 7.06) 5.57, (4.905, 6.48) 0.001 0.116 
Peak8 (NA3) 6.52, (5.08, 8.66) 7.35, (6.18, 8.37) 8.07, (6.69, 9.38) 0.118 <0.001 
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Peak9 (NA2Fb) 4.93, (3.89, 6.34) 2.55, (1.92, 3.49) 2.25, (1.61, 3.11) <0.001 <0.001 
Peak9' (NA3F) 1.09, (0.83, 1.43) 0.81, (0.66, 1.02) 0.86, (0.73, 0.97) <0.001 <0.001 
Peak10 (NA3F2) 0.63, (0.47, 0.822) 0.28, (0.19, 0.39) 0.26, (0.21, 0.325) <0.001 <0.001 
Peak11 (NA4) 1.38, (0.93, 2.03) 1.78, (1.38, 2.25) 1.8, (1.52, 2.18) 0.004 <0.001 
Peak12 (NA4Fb) 0.80, (0.65, 1.00) 0.53, (0.41, 0.84) 0.49, (0.33, 0.655) <0.001 <0.001 
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Table 3. Diagnostic power of each index in differentiating ECCA from healthy individuals 
Cut-off value Test Result 
Actual Status 
Sen (%) Spe (%) PPV (%) NPV (%) Accuracy (%)  
ECCA+ ECCA- 
CA19-9 
(32.00U/ml) 
ECCA+ 88 0 83.0 100.0 100.0 83.2 90.8 
 
ECCA- 18 89 
     
Peak10 (0.38) ECCA+ 92 9 86.8 90.0 91.1 85.1 88.2 
 
ECCA- 14 80 
     
Glycotest1 (1.83) ECCA+ 95 0 89.6 100.0 100.0 89.0 94.4 
 
ECCA- 11 89   
    
Glycotest1=0.089*CA19-9+11.444*peak10-0.331*peak5-0.540*peak6+17.058 
Sen: Sensitivity; Spe: Specificity; PPV: Positive predictive value; NPV: Negative predictive value 
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Table 4. Diagnostic power of each index in differentiating ECCA from BBD 
Cut-off value Test Result 
Actual Status 
Sen (%) Spe (%) PPV (%) NPV (%) Accuracy (%)  
ECCA+ ECCA- 
CA19-9 
(32.00U/ml) 
ECCA+ 88 10 83.0 83.3 89.8 73.5 83.1 
 
ECCA- 18 50 
     
Peak10 (0.49) ECCA+ 78 6 73.6 90.0 92.9 65.9 79.5 
 
ECCA- 28 54 
     
Glycotest2 (0.56) ECCA+ 90 4 84.9 93.3 95.7 77.8 88.0 
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ECCA- 16 56 
     
Glycotest2=0.009*CA19-9+9.112*peak10-4.370 
Sen: Sensitivity; Spe: Specificity; PPV: Positive predictive value; NPV: Negativpredictive value 
